Trial · NCT02601209
Participant flow54
How many started, completed or left each group, period by period.
1 to 20 of 54
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Initial Treatment (Up to 4 Months) | STARTED | Phase I - Dose Level 0 | 4 | |
| Initial Treatment (Up to 4 Months) | STARTED | Phase I - Dose Level 1 | 4 | |
| Initial Treatment (Up to 4 Months) | STARTED | Phase I - Dose Level 2 | 4 | |
| Initial Treatment (Up to 4 Months) | STARTED | Phase II - Analysis Group 1 Pazopanib | 6 | |
| Initial Treatment (Up to 4 Months) | STARTED | Phase II - Analysis Group 1 MLN0128 | 13 | |
| Initial Treatment (Up to 4 Months) | STARTED | Phase II - Analysis Group 2 Pazopanib | 15 | |
| Initial Treatment (Up to 4 Months) | STARTED | Phase II - Analysis Group 2 MLN0128 | 56 | |
| Initial Treatment (Up to 4 Months) | STARTED | Phase II - Analysis Group 1 Pazopanib Crossover | 6 | |
| Initial Treatment (Up to 4 Months) | STARTED | Phase II - Analysis Group 2 Pazopanib Crossover | 43 | |
| Initial Treatment (Up to 4 Months) | COMPLETED | Phase I - Dose Level 0 | 3 | |
| Initial Treatment (Up to 4 Months) | COMPLETED | Phase I - Dose Level 1 | 3 | |
| Initial Treatment (Up to 4 Months) | COMPLETED | Phase I - Dose Level 2 | 3 | |
| Initial Treatment (Up to 4 Months) | COMPLETED | Phase II - Analysis Group 1 Pazopanib | 6 | |
| Initial Treatment (Up to 4 Months) | COMPLETED | Phase II - Analysis Group 1 MLN0128 | 12 | |
| Initial Treatment (Up to 4 Months) | COMPLETED | Phase II - Analysis Group 2 Pazopanib | 13 | |
| Initial Treatment (Up to 4 Months) | COMPLETED | Phase II - Analysis Group 2 MLN0128 | 55 | |
| Initial Treatment (Up to 4 Months) | COMPLETED | Phase II - Analysis Group 1 Pazopanib Crossover | 6 | |
| Initial Treatment (Up to 4 Months) | COMPLETED | Phase II - Analysis Group 2 Pazopanib Crossover | 43 | |
| Initial Treatment (Up to 4 Months) | NOT COMPLETED | Phase I - Dose Level 0 | 1 | |
| Initial Treatment (Up to 4 Months) | NOT COMPLETED | Phase I - Dose Level 1 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02601209/flow